Cargando…

Molecular pathogenesis of the myeloproliferative neoplasms

The Philadelphia negative myeloproliferative neoplasms (MPN) compromise a heterogeneous group of clonal myeloid stem cell disorders comprising polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. Despite distinct clinical entities, these disorders are linked by morphological sim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Greenfield, Graeme, McMullin, Mary Frances, Mills, Ken
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246678/ https://www.ncbi.nlm.nih.gov/pubmed/34193229 http://dx.doi.org/10.1186/s13045-021-01116-z

Ejemplares similares

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2018)

Epigenetics in myeloproliferative neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2023)

Epigenetics in Myeloproliferative Neoplasms
por: McPherson, Suzanne, et al.
Publicado: (2017)

Modification of the Histone Landscape with JAK Inhibition in Myeloproliferative Neoplasms
por: Greenfield, Graeme, et al.
Publicado: (2020)

Aetiology of Myeloproliferative Neoplasms
por: McMullin, Mary Frances, et al.
Publicado: (2020)

Splanchnic venous thrombosis in JAK2 V617F mutation positive myeloproliferative neoplasms – long term follow-up of a regional case series
por: Greenfield, Graeme, et al.
Publicado: (2018)

Modifiable Lifestyle and Medical Risk Factors Associated With Myeloproliferative Neoplasms
por: Duncombe, Andrew S., et al.
Publicado: (2020)

Patient perspectives of a diagnosis of myeloproliferative neoplasm in a case control study
por: McMullin, Mary Frances, et al.
Publicado: (2016)

JAK2 V617F: A Single Mutation in the Myeloproliferative Group of Disorders
por: McLornan, Donal, et al.
Publicado: (2006)

(32)P in the treatment of myeloproliferative disorders
por: Lawless, Sarah, et al.
Publicado: (2016)

Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications
por: Morsia, Erika, et al.
Publicado: (2022)

The JAK2(V617F) mutation and the role of therapeutic agents in alleviating myeloproliferative neoplasm symptom burden
por: Orbell, Lai Yee, et al.
Publicado: (2023)

Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation
por: Hermouet, Sylvie, et al.
Publicado: (2015)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
por: Campregher, Paulo Vidal, et al.
Publicado: (2012)

Synoptic Diagnostics of Myeloproliferative Neoplasms: Morphology and Molecular Genetics
por: Nann, Dominik, et al.
Publicado: (2021)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
por: Jang, Mi-Ae, et al.
Publicado: (2020)

Significance of NPM1 Gene Mutations in AML
por: Hindley, Andrew, et al.
Publicado: (2021)

Guidelines for the management of myeloproliferative neoplasms
por: Choi, Chul Won, et al.
Publicado: (2015)

Targeted therapies for myeloproliferative neoplasms
por: Li, Bing, et al.
Publicado: (2019)

Experimental Modeling of Myeloproliferative Neoplasms
por: Lanikova, Lucie, et al.
Publicado: (2019)

Novel therapeutics in myeloproliferative neoplasms
por: Venugopal, Sangeetha, et al.
Publicado: (2020)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Genetic Background of Congenital Erythrocytosis
por: McMullin, Mary Frances
Publicado: (2021)

Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
por: Chatain, Nicolas, et al.
Publicado: (2020)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
por: Loscocco, Giuseppe G., et al.
Publicado: (2021)

Recent Advances in Molecular Diagnostics and Targeted Therapy of Myeloproliferative Neoplasms
por: Stivala, Simona, et al.
Publicado: (2021)

Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology
por: Chia, Yuh Cai, et al.
Publicado: (2023)

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology
por: Combaluzier, Sophie, et al.
Publicado: (2023)

Molecular Studies for the Early Detection of Philadelphia-Negative Myeloproliferative Neoplasms
por: Stuckey, Ruth, et al.
Publicado: (2023)

The Hematopoietic Niche in Myeloproliferative Neoplasms
por: Schmitt-Graeff, Annette H., et al.
Publicado: (2015)

Mutant Calreticulin in the Myeloproliferative Neoplasms
por: Prins, Daniel, et al.
Publicado: (2020)

Apoptosis deregulation in myeloproliferative neoplasms
por: Tognon, Raquel, et al.
Publicado: (2013)

Genetic basis and molecular profiling in myeloproliferative neoplasms
por: Luque Paz, Damien, et al.
Publicado: (2023)

Genetic Aspects of Myelodysplastic/Myeloproliferative Neoplasms
por: Palomo, Laura, et al.
Publicado: (2021)

NK Cells in Myeloproliferative Neoplasms (MPN)
por: Naismith, Erin, et al.
Publicado: (2021)

Functional Consequences of Mutations in Myeloproliferative Neoplasms
por: Constantinescu, Stefan N., et al.
Publicado: (2021)

Clonal Hematopoiesis and Mutations of Myeloproliferative Neoplasms
por: Kjær, Lasse
Publicado: (2020)

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
por: Gianelli, Umberto, et al.
Publicado: (2022)

Genetic Landscape of Myeloproliferative Neoplasms with an Emphasis on Molecular Diagnostic Laboratory Testing
por: Easwar, Arti, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eoflaltteb4ts8qokoqq90es4a